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ABSTRACT
During culture expansion, multipotent mesenchymal stromal cells (MSCs) differentially express
aldehyde dehydrogenase (ALDH), an intracellular detoxiﬁcation enzyme that protects long-lived
cells against oxidative stress. Thus, MSC selection based on ALDH-activity may be used to reduce
heterogeneity and distinguish MSC subsets with improved regenerative potency. After expansion
of human bone marrow-derived MSCs, cell progeny was puriﬁed based on low versus high ALDHactivity (ALDHhi) by ﬂuorescence-activated cell sorting, and each subset was compared for multipotent stromal and provascular regenerative functions. Both ALDHl8 and ALDHhi MSC subsets demonstrated similar expression of stromal cell (>95% CD731, CD901, CD1051) and pericyte (>95%
CD1461) surface markers and showed multipotent differentiation into bone, cartilage, and adipose
cells in vitro. Conditioned media (CDM) generated by ALDHhi MSCs demonstrated a potent proliferative and prosurvival effect on human microvascular endothelial cells (HMVECs) under serum-free
conditions and augmented HMVEC tube-forming capacity in growth factor-reduced matrices. After
subcutaneous transplantation within directed in vivo angiogenesis assay implants into immunodeﬁcient mice, ALDHhi MSC or CDM produced by ALDHhi MSC signiﬁcantly augmented murine vascular
cell recruitment and perfused vessel inﬁltration compared with ALDHl8 MSC. Although both subsets demonstrated strikingly similar mRNA expression patterns, quantitative proteomic analyses
performed on subset-speciﬁc CDM revealed the ALDHhi MSC subset uniquely secreted multiple
proangiogenic cytokines (vascular endothelial growth factor beta, platelet derived growth factor
alpha, and angiogenin) and actively produced multiple factors with chemoattractant (transforming
growth factor-b, C-X-C motif chemokine ligand 1, 2, and 3 (GRO), C-C motif chemokine ligand 5
(RANTES), monocyte chemotactic protein 1 (MCP-1), interleukin [IL]-6, IL-8) and matrix-modifying
functions (tissue inhibitor of metalloprotinase 1 & 2 (TIMP1/2)). Collectively, MSCs selected for
ALDHhi demonstrated enhanced proangiogenic secretory functions and represent a puriﬁed MSC
subset amenable for vascular regenerative applications. STEM CELLS 2017;35:1542–1553

SIGNIFICANCE STATEMENT
Applying core stem cell concepts using aldehyde dehydrogenase (ALDH) as a conserved marker of
primitive progenitor cells, mesenchymal stromal cells (MSCs) appear to have a functional hierarchy
where vascular regenerative potential is diminished as ALDH activity is reduced with cell differentiation. Purified ALDHlo and ALDHhi MSCs demonstrated clear secretory differences after purification,
which correlated with EC activation in vitro and enhanced stimulation of proangiogenic processes
in vivo. Thus, ALDHhi MSC represent a proangiogenic MSC subset with regenerative potential applicable to the development of cell therapies to augment therapeutic revascularization.

INTRODUCTION
Peripheral artery disease (PAD) is characterized
by ischemia in the lower extremities due to
narrowing of blood vessels associated with
atherosclerotic plaque accumulation. PAD currently affects 8–12 million in North America
and >200 million worldwide [1]. The clinical
consequences of PAD range from intermittent
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claudication, to critical limb ischemia (CLI), the
most severe form of PAD distinguished by pain
at rest with nonhealing ulcers in distal extremities. Many patients with CLI are not candidates for vessel bypass or percutaneous
interventions [2, 3], and approximately 30%
will require limb amputation. Those afﬂicted
with CLI have sixfold increased risk of serious
C AlphaMed Press 2017
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cardiovascular events [4], and >60% of CLI patients will die
from complications within 5 years of diagnosis [5]. Thus, there
is a compelling need for improved therapies to combat CLI.
Cell transplantation to restore perfusion in ischemic limbs
is under intense investigation for the treatment of CLI. In
2002, the therapeutic angiogenesis by cell transplantation
(TACT) trial ﬁrst demonstrated improvements in ankle brachial
pressure index and tissue oxygen saturation after transplantation of bone marrow mononuclear cells (BM MNCs) [6]. In a
follow-up study, there was signiﬁcant improvement in pain
scale and ulcer healing after 2 years post-transplantation [7].
Unfortunately, overall clinical beneﬁt was considered modest
and lower limb amputation rates were not improved. However, BM MNCs contain cells from multiple (hematopoietic,
endothelial, and mesenchymal–stromal) cell lineages that
directly or indirectly aid in neovessel formation [8].
In efforts to purify provascular progenitor cell populations
from human BM and umbilical cord blood (UCB) with
enhanced regenerative functions, we used a clinically applicable ﬂuorescent substrate (Aldeﬂuor) of aldehyde dehydrogenase (ALDH), a conserved detoxiﬁcation enzyme highly
expressed in multiple mesodermal progenitor cell lineages [9].
Essentially, ALDH protects long-lived cells against oxidative
environmental insults, and paradoxically represents the ratelimiting enzyme in the intracellular production of the lipid
morphogen, retinoic acid. As progenitor cell differentiation
occurs toward a more restricted or expendable phenotype,
ALDH-activity is generally reduced. Although cells with high
aldehyde dehydrogenase-activity (ALDHhi) represent a rare
fraction of human BM (<0.8% of MNC) or UCB (<0.5% of
MNC), ALDHhi cells are highly enriched for expandable progenitor cells with hematopoietic, endothelial, and mesenchymal
colony-forming functions [10]. Human cells with ALDHhi demonstrate a plethora of regenerative functions when transplanted into preclinical immunodeﬁcient mouse models,
including strong hematopoietic reconstituting capacity [11,
12], widespread tissue distribution after intravenous delivery
[12], elicit islet repair in models of diabetes [13, 14], and
demonstrate potent angiogenic stimulatory capacity in ischemic hindlimbs after femoral artery ligation [10, 15]. Recently,
a phase I, randomized controlled trial compared unselected
autologous BM MNC to puriﬁed BM ALDHhi cells in the treatment of CLI [16]. Although signiﬁcant improvements in ankle–
brachial index were observed in both groups, neither ischemic
group showed improvement in ischemic ulcer grade or limb
salvage [16].
Mesenchymal stromal cells (MSCs) are deﬁned as nonhematopoietic, progenitor cells that grow adherent to plastic
and differentiate into bone, cartilage, and adipose in vitro
[17]. MSCs are also considered potent biofactories that
orchestrate regenerative and immunomodulatory effects in a
paracrine fashion at sites of tissue injury [18–21]. BM-derived
MSCs promote survival and proliferation of endothelial cells
(ECs) under hypoxic conditions [22]. After transplantation,
MSCs home to sites of vascular injury, incorporate into vessels
as perivascular cells [23, 24], and secrete factors that support
angiogenesis such as vascular endothelial growth factor
(VEGF) and platelet derived growth factor (PDGF) [25]. Administration of ECs with MSCs has been shown to increase vascularization and enhance vessel stability in multiple murine
xenograft transplantation models [24, 26]. MSCs have been
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demonstrated to be safe and well tolerated in many clinical
studies [27, 28]. Early trials involving intramuscular transplantation into patients with CLI showed increased ankle brachial
pressure index, accelerated ulcer healing, and improving overall quality of life and Rutherford scores [29–31]. In a direct
comparison of autologous BM MNC to BM MSC administered
to patients with CLI, Lu et al. found that MSC-injected
patients showed better perfusion and ulceration recovery
scores at 6 months post-transplantation [32]. However, limb
salvage compared with MNC administration was not improved
by MSC treatment. Overall, MSCs represent an attractive cell
type to promote vascular regeneration because MSC can be
readily obtained from autologous and allogeneic sources,
expanded efﬁciently in culture, and support angiogenesis
while demonstrating very low immunogenicity [21]. However,
signiﬁcant challenges remain that prevent the advancement
of cellular therapies for CLI, and scientists have been challenged to better understand the functions of active cell subtypes that mediate beneﬁcial effects within heterogeous cell
populations. Here, we demonstrate that puriﬁcation using
ALDHhi after expansion selects a novel MSC subset with a
unique secretory proﬁle that augments EC survival, proliferation, tube formation in vitro and promotes the generation of
a proangiogenic niche in vivo.

MATERIALS

AND

METHODS

Selection of ALDHl8 versus ALDHhi MSC Subsets
Human BM aspirates were obtained from healthy allogeneic
sibling donors with informed consent from the London Health
Sciences Centre (London, ON). MNC were isolated via
hypaque-ﬁcoll centrifugation and seeded on tissue culture
plastic at 270,000 cells per square centimeter. Adherent stromal colonies (colony forming units–ﬁbroblast) were established within 14 days and expanded in Amniomax
media 1 supplement (Life Technologies, Carlsbad, CA, www.
thermoﬁsher.com).
At passage 4 (P4), MSCs were puriﬁed into ALDHl8 versus
ALDHhi subsets by ﬂuorescence activated cell sorting (FACS)
using the Aldeﬂuor assay (StemCell Technologies, Vancouver,
BC, www.stemcell.com) as described previously [11, 33]. The
ALDHhi subset represented cells with approximately Five-fold
higher ﬂuorescence intensity compared with ALDHl8 gate
established using DEAB-inhibition. Puriﬁed ALDHl8 and ALDHhi
MSC subsets also represented no greater than the top or bottom 30% of ALDH ﬂuorescent events, respectively. All BM
samples were sorted (FACS Aria III, Beckton Dickenson (BD),
Mississauga, ON, www.bdbiosciences.com) in the London
Regional Flow Cytometry Facility.

Cell Surface Phenotype Analysis
ALDHl8 and ALDHhi MSCs were costained with antibodies for
stromal cell markers: CD73, CD90, and CD105; hematopoietic
lineage markers: CD45 and CD14 (monocytes), and the pericellular marker: CD146. Surface marker expression was
obtained using an LSR II ﬂow cytometer (Beckton Dickenson)
and analysis performed using FloJo software (Treestar, Ashland, OR, www.ﬂowjo.com).
C AlphaMed Press 2017
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In Vitro Differentiation Assays
l

hi

To assess multipotent differentiation, ALDH 8 or ALDH MSCs
(N 5 3) were grown in adipogenesis or osteogenesis differentiation media (Life Technologies) as per manufacturer’s instructions. After 14 or 21 days, cells were ﬁxed in formalin and
stained for adipocytes or osteocytes using using oil red O or
Alizarin red, respectively. For chondrogenic differentiation,
micromasses of puriﬁed ALDHl8 or ALDHhi MSCs (N 5 3) were
cultured for 14 days in chondrogenesis differentiation media
(Life Technologies) as described previously [33]. Micromasses
were frozen in optimal cutting temperature (OCT), sectioned,
and stained with Alcian Blue counterstained with Nuclear Fast
Red.

Generation of Conditioned Media
FACS-puriﬁed ALDHl8 and ALDHhi MSC subsets were plated at
equal density (13,000 cells per square centimeter) and
allowed to recover for 8 hours in Amniomax media 1 supplement. After cell adherence, media were replaced with serum
and growth-factor deprived endothelial basal media (EBM-2,
Lonza, Walkersville, MD, www.lonza.com) and conditioned for
48 hours before using in subsequent experiments.

HMVEC Expansion Assays
HMVECs (9,400 cells per square centimeter) were cultured in
EBM-2, or in conditioned media (CDM) generated by puriﬁed
ALDHl8 or ALDHhi MSC subsets generated as described above. As
a positive control, HMVECs were also grown in complete endothelial growth medium (EGM-2 5 EBM-2 1 5% Fetal bovine
serum (FBS) 1 insulin-like growth factor, basic ﬁbroblast growth
factor [bFGF], Epidermal growth factor, VEGF). Viable HMVECs
were enumerated after 72 hours using blinded trypan blue exclusion hemocytometer counts. To assess cell survival and apoptosis
kinetics, HMVECs were harvested at 24, 48, and 72 hours analyzed by ﬂow cytometry for Annexin V/7-aminoactinomycin D (7AAD). To quantify cell proliferation, 500 nM EdU was supplemented into HMVEC cultures 24 hours before each timepoint.
HMVECs were ﬁxed and permeabilized using 10% formalin and
0.1% Triton X, and stained for nuclear EdU-incorporation using
the Click-It assay as per manufacturer’s instructions (Life Technologies). Edu-incorporation into proliferating cells was quantiﬁed
by ﬂow cytometry.
Direct contact cocultures between HMVEC and MSC subsets were also performed. HMVEC (9,400 cells per square millmeter) were seeded at a 1:1 ratio with ALDHl8 or ALDHhi
MSCs and cocultured in EBM-2 for up to 72 hours. HMVEC
alone or ALDHl8 or ALDHhi MSCs alone were cultured in EBM2 as controls. Cell survival and proliferation for each cell type
was quantiﬁed by ﬂow cytometry as described above with
addition of CD31 and CD90 antibodies to discern endothelial
versus stromal cell types respectively, at each timepoint (24
hours, 48 hours, and 72 hours) in mixed cultures.

HMVEC Tubule Forming Assays
To assay for tubule forming function in vitro, 120,000 HMVEC
were cultured on growth factor-reduced Geltrex matrices (Life
Technologies) in EBM-2 or in CDM generated from ALDHl8 versus ALDHhi MSC subsets. After 24 hours, four photomicrographs were taken per well, and tube formation was
C AlphaMed Press 2017
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quantiﬁed by manual counting of complete tubes using
ImageJ software.

Directed In Vivo Angiogenesis Assay
To compare the proangiogenic capacity of ALDHl8 versus
ALDHhi MSC subsets in vivo, the directed in vivo angiogenesis
assay (DIVAA) was performed as per manufacturer’s instructions (Trevigen, Gaithersburg, MD, www.trevigen.com). DIVAA
inserts with 200,000 ALDHl8 and ALDHhi MSCs suspended in
20 ml basement membrane extract were subcutaneously
implanted into the ﬂank of Non-obese diabetic/Severe combined immunodeﬁciency (NOD/SCID) mice. After 10 days in
vivo, EC recruitment into each angioreactor was quantiﬁed by
lectin-uptake, using a SpectraMax plate reader (Molecular
Devices, Sunnyvale, CA, www.moleculardevices.com).

Microarray Analyses
mRNA was extracted from 5 3 105 ALDHl8 and ALDHhi MSCs
(N 5 3) using mRNAeasy mini kits (Qiagen, Dusseldorf, Germany, www.qiagen.com). Sample matched and early passage (P4)
MSCs were used to minimize heterogeneity. Nanodrop readings were taken to determine mRNA quality and concentration, and mRNA expression was assessed using Affymetrix
1.0ST human gene array chips (Affymetrix, Santa Clara, CA,
www.affymetrix.com) at the London Regional Genomics Facility. Data were analyzed using Partek Genomics Suite software
(Partek Inc., St. Louis, MO, www.partek.com).

Proteomic Analyses of CDM
CDM from puriﬁed MSC samples (N 5 3) was generated in
biological duplicate and concentrated (approximately 50-fold)
using 3 kDa centrifugal ﬁlter units (Millipore, Darmstadt, Germany, www.emdmillipore.com). Frozen and lyophilized protein
extracts were resuspended in 8 M urea, 50 mM ammonium
bicarbonate, 10 mM dithiothreitol, and 2% SDS. Protein concentration was measured using the Pierce protein assay (ThermoFisher), and 150 lg total protein was fractionation with
SDS-polyacrylamide gel electrophoresis using 8%–20% gels in
technical duplicate. Samples were digested using an in-gel
protocol with trypsin/LysC (Promega, Madison, Wisconsin,
www.promega.com) as described previously [34]. Prepared
fractions were injected and separated using a nanoAcuity system (Waters, Milford, MA, www.waters.com) on a 25-cm long
3 75 lm inner diameter C18 column maintained at 358C. All
samples were trapped for 5 minutes at 99% H2O, 1% acetonitrile, and separated using a 5.0% to 32.5% acetonitrile gradient over 74 minutes, followed by 60% acetonitrile over 6
minutes, at a ﬂow rate of 300 nl/minutes. Fractions were
quantiﬁed using the bicinchroninic acid (BCA) assay (ThermoFisher Scientiﬁc) and 1 lg of material was injected per fraction. Mass spectrometry was performed on an Orbitrap Elite
(ThermoFisher Scientiﬁc). Full MS parameters are outlined in
Supporting Information Table S1. Data analysis was performed
with MaxQuant version 1.5.0.30 using the Andromeda search
engine [35]. MS/MS spectra were searched against the Human
Uniprot database with trypsin speciﬁcity (20,264 entries) [36].
Bioinformatic analysis was performed using Perseus version
1.5.0.8. Datasets were ﬁltered for proteins containing a minimum of one unique peptide.
STEM CELLS
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Cytokine Arrays
The human angiogenesis array C1 (RayBiotech, Norcross, GA,
www.raybiotech.com) was used to compare angiogenesisassociated protein composition within CDM from ALDHl8 and
ALDHhi MSC (N 5 4). The cytokine arrays were prepared as
per manufacturer’s instructions and imaged using the Bio-Rad
Gel Documentation System (Bio-Rad, Hercules, CA, www.biorad.com). The relative intensity units for each array feature
were quantiﬁed by densitometry using the microarray plugin
for ImageJ.

Statistical Analysis
Analysis of signiﬁcance for mRNA expression was performed
using Partek using algorithms for data normalization, analysis
of variance (ANOVA), and false discovery rates (<0.05). A multiple sample T-test was performed in Perseus comparing the
ALDHl8 versus ALDHhi MSC CDM. Analysis of signiﬁcance was
performed by one-way ANOVA with Tukey’s multiple comparison tests for the cell survival and proliferation assays, tubuleformation assays, and for the DIVAA experiments.

RESULTS
ALDHl8 and ALDHhi MSCs Demonstrated Multipotent
Differentiation Potential In Vitro
At passage 4 (P4), bulk MSCs were puriﬁed based on ALDHactivity using the Aldeﬂuor assay, selecting the top and bottom 30% of ﬂuorescent events while maintaining approximately ﬁvefold difference in ﬂuorescence intensity between
ALDHl8 and ALDHhi subsets based on DEAB-inhibited controls
(Fig. 1A). The ALDHl8 and ALDHhi subsets were ﬁrst assessed
for stromal, pericyte, endothelial, and hematopoietic cell surface marker expression. Both subsets showed >95% expression of the stromal markers CD73, CD90, CD105, and the
pericyte marker CD146. In contrast, <1% of cells expressed
endothelial (CD31) or hematopoietic cell (CD45 and CD14)
markers (Fig. 1B, 1C). Thus, both subsets represented pure
stromal cell populations without signiﬁcant hematopoietic or
EC contamination. Next, we performed multipotent differentiation on ALDHl8 and ALDHhi subsets. As predicted by cell surface marker expression, both the ALDHl8 and ALDHhi subsets
equally retained multipotent differentiative capacity into fat,
bone, and cartilage lineages in vitro (Fig. 1D, 1E). Collectively,
both the ALDHl8 and ALDHhi subsets equally fulﬁll the minimal
criteria for MSCs established by the International Society of
Cellular Therapy [17].

CDM Generated by ALDHl8 or ALDHhi MSCs
Augmented HMVEC Expansion In Vitro
To compare the angiogenesis stimulatory potential of the
ALDH-puriﬁed MSC subsets, HMVECs were grown in CDM
generated by ALDHl8 versus ALDHhi MSCs and cell proliferation
and survival were quantiﬁed ﬂow cytometric analyses measuring EdU-incorporation and 7-AAD/Annexin V detection of apoptotic cells. Representative dot plots for each analysis are
shown in Supporting Information Figure S1. Compared with
HMVECs cultured under serum-starved, growth factor-free
basal conditions (EBM-2), exposure to ALDHl8 or ALDHhi CDM
for 72 hours signiﬁcantly increased overall HMVEC expansion
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(Fig. 2A). After 48 hours exposure to ALDHl8 or ALDHhi MSC
CDM, HMVECs exhibited increased proliferation (Fig. 2B) and
decreased apoptosis (7-AAD-/AnnexinV1) (Fig. 2C). The frequency of dead HMVECs (7-AAD1/AnnexinV1) was also
reduced after 72 hours exposure to ALDHl8 or ALDHhi MSC
CDM (Fig. 2D). Thus, CDM from ALDHl8 or ALDHhi MSCs
enhanced HMVEC survival and proliferation under growth factor depleted conditions in vitro

Contact Coculture with ALDHl8 or ALDHhi MSCs Did
Not Promote HMVEC Expansion
To assess whether cell contact could further stimulate EC
growth, puriﬁed MSC subsets were cultured in direct contact
with HMVEC under serum-free, growth factor-deprived conditions. Endothelial versus stromal cell phenotype was discerned in mixed cultures using selective CD31 and CD90
expression along-side proliferation and apoptosis assays. Surprisingly, coculture with ALDHl8 or ALDHhi MSCs for 72 hours
did not augment total HMVEC number compared with uniculture in EBM-2 (Fig. 3A). In fact, contact coculture with ALDHl8
or ALDHhi MSCs signiﬁcantly decreased HMVEC proliferation
(Fig. 3B). Although direct coculture with ALDHl8 and ALDHhi
MSC signiﬁcantly decreased the frequency of apoptotic
HMVEC at 72 hours (Fig. 3C), there was no difference in the
frequency of dead HMVEC over the 72-hour time course (Fig.
3D). Conversely, coculture with HMVEC signiﬁcantly increased
MSC expansion under serum-free, growth factor-deprived conditions (Supporting Information Fig. S2A). During direct coculture with HMVEC, the ALDHl8 and ALDHhi MSC subsets
signiﬁcantly increased EdU incorporation at 72 hours compared with the MSC subsets cultured alone (Supporting Information Fig. S2B). Although no changes were observed in the
frequency of apoptotic MSCs over 72 hours (Supporting Information Fig. S2C), the frequency of dead MSCs was signiﬁcantly reduced in ALDHl8 and ALDHhi MSCs cocultures at 48 hours
compared with the individual MSC controls (Supporting Information Fig. S2D). Contrary to our predicted results, HMVEC
presence promoted MSC expansion, whereas MSC presence
did not promote HMVEC survival of proliferation under
growth factor-restricted conditions.

ALDHhi MSC CDM Augmented HMVEC Tube Formation
Using a similar strategy to measure HMVEC function, HMVEC
were exposed to CDM generated from ALDHl8 or ALDHhi MSC
subsets and spontaneous tubule formation was quantiﬁed in
growth factor-reduced Geltrex matricies (Fig. 4A–4D).
Although proliferative and prosurvival effects were demonstrated by CDM from both MSC subsets, only CDM generated
by ALDHhi MSC augmented tube forming capacity in vitro
compared with the EBM-2 condition (Fig. 4E).

ALDHhi MSC Augmented EC Recruitment into DIVAA
Inserts
To assess angiogenesis stimulatory function by human MSC
subsets in vivo, 2 3 105 ALDHl8 or ALDHhi MSC were loaded
into DIVAA inserts and subcutaneously implanted into NOD/
SCID mice for 10 days. Representative images of the excised
angioreactors show erythrocyte invasion into the ALDHhi MSC
containing angioreactor similar to VEGF/FGF containing controls (Fig. 5A). After measurement of lectin uptake in 6–9
DIVAA inserts per group, the ALDHhi MSC subset signiﬁcantly
C AlphaMed Press 2017
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Figure 1. Aldehyde dehydrogenase (ALDH)l8 and ALDHhi mesenchymal stromal cell (MSC) subsets expressed stromal and pericyte
markers and demonstrated multipotent differentiation in vitro. (A): Representative ﬂow cytometry plots showing the selection of human
BM-derived MSC with low versus high ALDH-activity (ALDHhi). ALDHhi MSC were deﬁned as approximately ﬁvefold higher ﬂuorescence
than the DEAB control gate, and each subset represented <30% of total events at the bottom and top of ﬂuorescent intensity. (B):
ALDHl8 and (C) ALDHhi MSC subsets expressed cell surface markers indicating high stromal cell purity (>95% CD731, CD901, CD1051,
CD45–, CD14–). The perivascular cell marker CD146 was also detected on >95% of ALDHl8 and ALDHhi MSC. (D): ALDHl8 and (E) ALDHhi
MSCs demonstrated multipotent differentiation to chondrocytes, adipocytes, and osteocytes. Data are representative of experiments
comparing puriﬁed MSC from 4-6 human BM samples. Abbreviations: ALDH, aldehyde dehydrogenase; DEAB, diethylaminobenzaldehyde.
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Figure 2. Conditioned media generated by aldehyde dehydrogenase (ALDH)l8 or ALDHhi mesenchymal stromal cells (MSCs) stimulated
human microvascular endothelial cell (HMVEC) expansion in vitro. (A): Exposure to ALDHl8 or ALDHhi MSC conditioned media (CDM) for
72 hours augmented total HMVEC number compared with serum-free, growth factor-deprived conditions (endothelial basal media-2).
(B): ALDHl8 or ALDHhi MSC CDM increased the frequency of proliferating HMVEC at 48 hours. (C): ALDHl8 or ALDHhi MSC CDM decreased
the frequency of apoptotic HMVEC (7-aminoactinomycin D [7-AAD-]/AnnexinV1) at 48 and 72 hours. (D): ALDHl8 or ALDHhi MSC CDM
reduced the frequency of dead HMVEC (7-AAD1/Annexin V1) at 72 hours. Data represent mean 6 SEM using puriﬁed MSC CDM derived
from three human BM samples (**p < .01; ***p < .001). Abbreviations: 7-AAD, 7-aminoactinomycin D; CDM, conditioned media;
HMVEC, human microvascular endothelial cell; MSC, mesenchymal stromal cell.

increased EC content within the angioreactor compared with
the ALDHl8 MSC subset (Fig. 5B). Next, concentrated CDM
from ALDHl8 or ALDHhi MSC subsets was loaded into angioreactors and subcutaneously transplanted into NOD/SCID mice.
Lectin uptake was signiﬁcantly increased in inserts containing
ALDHhi MSC CDM compared with ALDHl8 MSC CDM or concentrated EBM-2. Thus, CDM generated speciﬁcally by the
ALDHhi MSC subset stimulated EC recruitment into angioreactors in vivo.

ALDHl8 and ALDHhi MSCs Demonstrated Similar mRNA
Expression
Affymetrix microarrays were performed to compare global
mRNA expression between ALDHl8 and ALDHhi MSC subsets.
As predicted by functional analyses using HMVEC coculture in
vitro, puriﬁed ALDHl8 and ALDHhi MSC showed remarkably
similar mRNA expression patterns. Volcano plot analyses
marked only 51 mRNAs with >1.2-fold differential expression
(p < .05) (Supporting Information Fig. S3A). Indeed, principal
component analyses indicated considerable sample variability
between each MSC line with lower variation between samplematched ALDHl8 and ALDHhi MSC subsets (Supporting Information Fig. S3B). Collectively, only 29 mRNAs showed
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increased expression (>1.2-fold, p < .05) comparing ALDHhi to
ALDHl8 MSC. Within these mRNAs, 11 had unknown function,
4 were non-coding, and 4 had pseudogene classiﬁcation. Conversely, only 21 mRNAs showed decreased expression (<-1.2fold, p < .05) in ALDHhi MSC. Within these mRNAs, 15 had
unknown function, were noncoding or had pseudogene classiﬁcation. Supporting Information Table S2 annotates the predicted functions of the 15 differentially expressed mRNAs
identiﬁed. Interestingly, ALDH1A3 mRNA expression was twofold increased in the ALDHhi MSC subset. Because ALDH1A3 is
a predominant isoform implicated in Aldeﬂuor metabolism,
increased ALDH1A3 expression is expected in MSCs selected
for ALDHhi and validate the accuracy of our sorting and subsequent mRNA expression analyses (Supporting Information
Table S2), Overall, mRNA expression between the ALDHl8 and
ALDHhi MSCs was remarkably similar, and the few differentially expressed mRNAs showed no obvious link to angiogenic
secretory functions.

ALDHhi MSC Demonstrated a Proangiogenic Secretome
ALDHl8 and ALDHhi MSC subsets (N 5 3) were incubated in
EBM-2 for 48 hours to generate CDM for global secretome
analyses using mass spectrometry. A total of 2,482 proteins
C AlphaMed Press 2017
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Figure 3. Contact coculture with aldehyde dehydrogenase (ALDH)l8 or ALDHhi mesenchymal stromal cells (MSCs) did not augment
human microvascular endothelial cell (HMVEC) expansion in vitro. (A): Coculture with ALDHl8 or ALDHhi MSC for 72 hours did not augment total HMVEC number compared with serum-free, growth factor-deprived conditions (endothelial basal media-2). (B): Coculture
with ALDHl8 and ALDHhi MSC decreased the frequency of proliferating HMVEC at 24 and 72 hours. (C): Coculture with ALDHl8 and
ALDHhi MSC decreased the frequency of apoptotic HMVEC (7-aminoactinomycin D (7-AAD-)/AnnexinV1) at 72 hours only. (D): Coculture
with ALDHl8 and ALDHhi MSCs did not change the frequency of dead HMVEC (7-AAD1/AnnexinV1). Data represent mean 6 SEM using
puriﬁed MSC from three human BM samples (**, p < .01; ***, p < .001). Abbreviations: 7-AAD, 7-aminoactinomycin D; ALDH, aldehyde
dehydrogenase; EGM, endothelial growth medium; HMVEC, human microvascular endothelial cell; MSC, mesenchymal stromal cell.

were detected, 501 proteins were unique to ALDHl8 MSC
CDM, 264 proteins were unique to ALDHhi MSC CDM, and
1,717 proteins were commonly produced by both subsets.
These lists were annotated and ﬁltered using gene ontology
(GO)-cellular component terms associated with the extracellular space or secreted fraction or signal peptide, inclusive of
membrane-bound proteins (92 peptides). As an additional criterion, we annotated and ﬁltered based on GO-molecular
function terms associated with angiogenesis (tube formation,
EC proliferation, migration, matrix modiﬁcation, etc.). These
analyses identiﬁed 10 cytokines unique to the ALDHhi CDM
(Table 1A) all associated with the positive regulation of angiogenesis. Several unique factors (VEGF beta [VEGFB], platelet
derived growth factor alpha [PDGFA], Plexin D1, Angiogenin)
were directly associated with EC proliferation, differentiation,
tubule formation, and migration, and several others were
important developmental factors (Wnt5A, Spondin1, and activin A receptor) linked angiogenic processes. No proteins
unique to the ALDHhi CDM had documented anti-angiogenic
effects (Table 1A). The 501 unique factors in the ALDHl8 CDM
were analyzed in an identical fashion and revealed nine
secreted proteins (Table 1B). Only one protein, angiopoietinlike 3 (ANGPTL3), had conﬁrmed proangiogenic activity,
whereas three proteins unique to the ALDHl8 MSC CDM
C AlphaMed Press 2017
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(platelet factor 4, tyrosine kinase 1 (TIE1), and plasminogen)
had documented anti-angiogenic functions (Table 1B).
A direct comparison of proteins common to the ALDHl8 and
ALDHhi secretome revealed few differences in the amount of
secreted products that were >1.5-fold or <-1.5-fold different
in ALDHhi MSC CDM compared with ALDHl8 MSC CDM (Supporting Information Fig. S4). Label-free quantitation intensities
in more than ﬁve of six sample replicates (1,351 peptides)
were again annotated and ﬁltered using GO-cellular component
terms associated with the extracellular space or secreted fraction, inclusive of membrane-bound proteins (698 peptides, Supporting Information Fig. 4), and a multiple sample T-test was
performed to obtain differentially secreted proteins (Table 2).
Interestingly, there were several factors secreted more highly in
the ALDHl8 MSC subset with the potential to promote (myeloid
derived growth factor and PLAUR), or inhibit angiogenic process
such as ADAMTS12 (Table 2).
To validate the proteomic analyses, ALDHl8 and ALDHhi
MSC subset CDM (48 hours in EBM-2) were also assayed for
cytokine/chemokine secretion using the Human Angiogenesis
array C1 multiplex-enzyme-linked immune sorbent assay.
ALDHhi MSC and ALDHl8 MSC showed similar secretory patterns with both MSC subsets secreted similar quantities of
angiogenin, C-X-C motif chemokine ligand 1, 2 and 3 (GRO),
STEM CELLS
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Figure 4. Conditioned media (CDM) generated by aldehyde dehydrogenase (ALDH)hi mesenchymal stromal cells (MSC) augmented
human microvascular endothelial cell (HMVEC) tube formation in vitro. (A–D): Representative images of HMVEC tube formation after 24
hours culture in growth factor reduced Geltrex matricies supplemented with (A) endothelial growth medium-2, (B) endothelial basal
media (EBM-2), (C) ALDHl8 MSC CDM, or (D) ALDHhi MSC CDM. White arrows indicate examples of enumerated complete tubule
branches. (E): CDM derived from the ALDHhi MSC subset augmented tube formation compared to HMVEC grown in EBM-2. All images
were acquired at a 43 magniﬁcation. Data are represented as mean 6 SEM using puriﬁed MSC from four human BM samples
(*p < .05). Abbreviations: ALDH, aldehyde dehydrogenase; CDM, conditioned media; EBM-2, endothelial basal media; EGM-2, endothelial
growth medium 2; MSC, mesenchymal stromal cell; HMVEC, human microvascular endothelial cell.

interleukin [IL]-6, IL-8, monocyte chemotactic protein 1 (MCP1), C-C motif chemokine ligand 5 (RANTES), transforming
growth factor-b, tissue inhibitor of metalloproteinases
(TIMP1/2), and VEGF (Supporting Information Fig. S5). Overall,
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these secretome analyses suggested the ALDHhi MSC subset
demonstrated a secretory proﬁle consistent with the stimulation of EC proliferation, migration, tube formation, and the
chemoattraction of proangiogenic accessory cells.
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Figure 5. Implantation of aldehyde dehydrogenase (ALDH)hi
mesenchymal stromal cells (MSCs) increased endothelial cell invasion into directed in vivo angiogenesis assay (DIVAA) inserts. (A):
Representative images of DIVAA inserts retrieved 10 days after
subcutaneous implantation. EC invasion was measured using
lectin-FITC uptake. (B): Implantation of ALDHhi MSC increased EC
invasion into the angioreactor compared to the ALDHl8 MSC. (C):
Concentrated conditioned media generated from the ALDHhi MSC
subset also increased EC invasion into the angioreactor. Data are
represented as mean 6 SEM for three human BM samples performed in triplicate (*, p < .05). Abbreviations: ALDH, aldehyde
dehydrogenase; CDM, conditioned media; EBM-2, endothelial basal media; FGF, ﬁbroblast growth factor; MSC, mesenchymal stromal cell; PBS, phosphate buffer saline; VEGF, vascular endothelial
growth factor.

DISCUSSION
Cultured MSC represent a heterogeneous mixture of stromal
cells amenable to novel cellular therapy applications, due to
purported immunomodulatory [37–39] and regenerative
C AlphaMed Press 2017
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paracrine effects [20, 21]. Here, we demonstrate expanded
MSC puriﬁed based on ALDHhi selects for an MSC sub-fraction
with enhanced proangiogenic characteristics. Direct comparison of ALDHl8 versus ALDHhi MSC subsets showed identical
cell surface marker expression and differentiation into bone,
cartilage, and adipose tissues in vitro. In addition, CDM from
both ALDHl8 and ALDHhi MSC subsets demonstrated remarkable effects on endothelial cell functions in vitro. Detailed
comparison of survival/proliferation kinetics every 24 hours
revealed MSC CDM increased HMVEC proliferation early in
culture (48 hours), and subsequently reduced apoptosis and
cell death later in culture (48–72 hours). Although CDM from
both MSC subtypes augmented HMVEC expansion, only
ALDHhi MSC CDM signiﬁcantly increased HMVEC tubule formation in vitro. Thus, only ALDHhi MSC CDM was able to support both endothelial cell expansion and tubule forming
functions in vitro.
Surprisingly, contact coculture with ALDHl8 or ALDHhi MSC
subsets did not augment HMVEC survival or proliferation in
serum-free EBM-2 media. In fact, HMVEC proliferation was
decreased during coculture, while MSC subset proliferation
and survival was increased. As reported previously by Dhahri
et al. [40], our coculture data suggested the presence of
HMVEC supported MSC expansion, while the presence of MSC
had little effect on HMVEC growth.
After incubation for 10 days in NOD/SCID mice, subcutaneously implanted DIVAA angioreactors containing ALDHhi
MSC or ALDHhi MSC CDM increased endogenous vascular cell
recruitment measured by lectin uptake. Interestingly, vascularization of angioreactors containing the ALDHhi MSC CDM was
equivalent to angioreactors containing a VEGF/FGF cocktail
used as a positive control. Futhermore, ALDHlo MSC or its
CDM did not promote endogenous cell recruitment compared
with control angioreactors. This data suggest that ALDHhi MSC
uniquely support the generation of a proangiogenic niche
through secretion of chemokines or cytokines that augment
recruitment or stimulate the activation of endogenous endothelial cells in vivo.
Puriﬁed ALDHl8 and ALDHhi MSC subsets were also compared for differences in mRNA expression using Affymetrix
arrays. The expression patterns of the ALDHl8 versus ALDHhi
MSC subsets were strikingly similar. Interestingly, PCA analysis
of the microarray data indicates that high variability exists
between each MSC line and lower variability exists between
ALDHl8 and ALDHhi MSC within samples. Indeed, the largest
mRNA expression difference two-fold between puriﬁed MSC
populations was ALDH1A3, reﬂecting the enzymatic function
used to sort the cells at the onset of experiments. Thus, analyses of transcription proﬁles using microarray did not account
for the enhanced capacity of ALDHhi MSC to induce proangiogenic processes.
Next, we carefully analyzed protein secretion into conditioned media (CDM) generated by ALDHl8 and ALDHhi MSC
subsets using highly sensitive proteomic techniques, as posttranscriptional regulation may permit small changes in transcription to give rise to larger changes in protein secretion.
Quantitative mass spectrometry analyses revealed that ALDHhi
MSC uniquely secreted several well-known proangiogenic
growth factors (VEGFB, PDGFA, and Angiogenin) not present
in the secretome of ALDHl8 MSC. Conversely, the ALDHl8 MSC
CDM contained potent anti-angiogenic factors (platelet factorSTEM CELLS
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Table 1. Secreted proteins unique to conditioned media generated by aldehyde dehydrogenase (ALDH)hi mesenchymal stromal cells
(MSCs) or ALDHlo MSCs
Protein

Gene name

Primary function

(A) Within ALDHhi MSC CDM, multiple unique factors were identiﬁed that were associated with the positive regulation of angiogenesis (bold)
Vascular endothelial growth factor beta
VEGFB
Positive regulation of angiogenesis, growth factor for endothelial cells
Platelet derived growth factor alpha
PDGFA
Positive regulation of angiogenesis, cell proliferation and differentiation.
Angiogenin
ANG
Positive regulation of angiogenesis, Induces vascularization in normal tissues
Plexin D1
PLXND1
Semaphorin receptor, regulation of endothelial cell migration
Insulin-like growth factor 1
IGF1
Stimulates cell proliferation, inhibits cell death
Gremlin 1
GREM1
Regulates embryonic patterning
Wingless type MMTV, 5A
WNT5A
Induces cell migration and regulates developmental pathways during development
Meteorin
METRN
glial cell differentiation, axon formation during neurogenesis
Spondin1
SPON1
Factor for vascular smooth muscle cells and neural outgrowth
Activin A Receptor, type 1
ACVR1
Binds and activates SMAD transcriptional regulators
(B) Proteins unique to the CDM generated by ALDHlo MSC were negative regulators of angiogenesis (italics).
Protein tyrosine phosphatase, type M
PTPRM
Involved in cell-cell adhesion. May be involved in growth regulation
Apolipoprotein H
APOH
Heparin-binding protein, involved in blood coagulation
Protein tyrosine phosphatase, type U
PTPRU
Cell proliferation, migration, maintenance of epithelial integrity
Platelet factor 4
PF4
Negative regulation of angiogenesis, inhibits endothelial cell proliferation
Tyrosine kinase 1
TIE1
Negative regulation of angiogenesis,antagonist of angiopoietin 1,
promotes vessel stability
Plasminogen
PLG
Negative regulation of angiogenesis, converted to plasmin and
angiostatin (anti-angiogenic)
Matrix metallopeptidase 19
MMP19
Protease involved in ECM degradation
Angiopoietin-like 3
ANGPTL3
Positive regulation of angiogenesis
Bone morphogenic protein 2
BMP2
Induces bone and cartilage formation
Unique peptides were identiﬁed with a false detection rate of 0.01, N 5 3 mesenchymal stromal cell samples performed in duplicate. Primary
functional annotations were obtained from GeneCards
Abbrevaitions: ALDH, aldehyde dehydrogenase; CDM, conditioned media; MMTV, mouse mammary tumor virus; MSC, mesenchymal stromal cell;
SMAD, mothers against decapentaplegic homolog.

Table 2. Proteins differentially secreted from aldehyde dehydrogenase (ALDH)hi versus ALDHlo mesenchymal stromal cells
Protein name

Prothymosin alpha
Thy-1 membrane glycoprotein
Proteoglycan 4
Cullin-associated NEDD8-dissociated protein 1
Biglycan
Neural cell adhesion molecule 1
Myeloid derived growth factor
Disintegrin and metalloproteinase
domain-containing protein 10
Ataxin-10
Fibronectin Leucine-rich transmembrane protein
Urokinase plasminogen activator surface receptor
Disintegrin and metalloproteinase with
thrombospondin motifs 12
Glypican-1
Insulin-like growth factor-binding protein 5
Ig gamma-1 chain C region (heavy chain)

Gene
name

Protein function

Fold change
(Ahi vs. Alo)

PTMA
THY1
PRG4
CAND1
BGN
NCAM1
C19orf10
ADAM10

May be involved in immune resistance
Plays a role in cell–cell/cell–ligand interactions
Prevents protein deposition onto cartilage in synovial joints
SCF assembly factor
Collagen ﬁbre assembly
Cell–cell interaction and cell–matrix interaction
Stimulates endothelial cell proliferation and cardiac cell survival
Cleaves cell surface proteins including TNF-alpha and E-cadherin

2.967
2.508
2.420
1.744
21.509
21.528
21.556
21.557

Neuron survival, differentiation, and neuritogenesis
cell adhesion, migration, and axon guidance
Promotes plasminogen formation/localization
Involved in aggrecan cleavage and anti-angiogenic properties

21.607
21.808
21.876
22.070

Cell division and growth regulation
Prolongs half life of insulin growth factors.
heavy chain immunoglobulin

22.497
22.540
22.992

ATXN10
FLRT2
PLAUR
ADAMTS12
GPC1
IGFBP5
IGHG1

Differentially secreted proteins (>1.5-fold difference) were detected in conditioned media generated by aldehyde dehydrogenase (ALDH)hi versus
ALDHlo mesenchymal stromal cells (MSCs). Overall, few proteins (only four) were observed to have >1.5-fold increased concentration in the
ALDHhi MSC subset. Of note, the ALDHlo MSC subset showed enhanced secretion of known pro- and anti-angiogenic proteins. Peptides identiﬁed
using at least one unique peptide with a false detection rate of 0.01, N 5 3, performed in duplicate. Functional annotations obtained from
GeneCards.org.

4 and plasminogen) not present in the ALDHhi MSC CDM. For
example, platelet factor 4, or CXCL4, was the ﬁrst chemokine
shown to inhibit endothelial cell proliferation and migration
via direct interaction and interference with bFGF, VEGF alpha
(VEGFA), and integrin signalling [41]. Plasminogen, through
proteolytic conversion to angiostatin enables inhibition of
angiogenesis through direct interaction with endothelial cells
[42, 43]. Hanahan and Folkman ﬁrst established the principles
of angiogenesis describing that vessel advancement or regression is controlled by a series of on/off switches within the
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microenvironment [44]. Using this model, the secretome of
ALDHl8 MSC was consistent with the promotion of antiangiogenic processes, whereas the ALDHhi MSC secretome
was consistent with the promotion of proangiogenic
processes.
This study outlines several advances relevant to the development of proangiogenic therapies. First, ALDHhi MSCs can be
puriﬁed after culture based on a conserved progenitor function where cell surface markers have not been successful
identifying MSC with speciﬁc regenerative functions. Second,
C AlphaMed Press 2017
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MSC selection can reduces heterogeneity and can purify an
“active” MSC subset with enhanced proangiogiogenic secretory functions. Third, the potential use of allogeneic ALDHhi
MSC for the treatment of ischemic diseases is an exciting possibility as mounting evidence indicates the potential for cellular dysfunction by autologous MSC in patients with
cardiovascular comorbidities. Finally, only the reselected MSC
progeny with ALDHhi retained proangiogenic niche forming
capacity after implantation in vivo. Thus, the delivery of BM
ALDHhi MSC into patients with CLI, may be used in future
clinical strategies to mediate proangiogenic beneﬁt.

In conclusion, ALDHhi MSCs represent a subset of expanded
MSC endowed with enhanced angiogenic potential. Using this
clinically applicable selection procedure, our laboratory has
previously identiﬁed hematopoietic progenitor cell populations from bone marrow and UCB with vascular regenerative
potential [10, 11]. Applying core stem cell concepts using
ALDH as a functional progenitor cell marker, MSCs appear to
have a functional hierarchy where vascular regenerative
potential is diminished as ALDH activity is reduced with cell
differentiation. Puriﬁed ALDHl8 and ALDHhi MSC demonstrated
clear secretory differences after puriﬁcation that correlated
with EC activation in vitro and enhanced stimulation of
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